JP2025508051A - 大うつ病性障害の治療に使用するためのアチカプラントの多形形態 - Google Patents
大うつ病性障害の治療に使用するためのアチカプラントの多形形態 Download PDFInfo
- Publication number
- JP2025508051A JP2025508051A JP2024553358A JP2024553358A JP2025508051A JP 2025508051 A JP2025508051 A JP 2025508051A JP 2024553358 A JP2024553358 A JP 2024553358A JP 2024553358 A JP2024553358 A JP 2024553358A JP 2025508051 A JP2025508051 A JP 2025508051A
- Authority
- JP
- Japan
- Prior art keywords
- aticaplant
- crystalline form
- atikaplant
- amorphous
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263317475P | 2022-03-07 | 2022-03-07 | |
| US63/317,475 | 2022-03-07 | ||
| PCT/IB2023/052088 WO2023170550A1 (en) | 2022-03-07 | 2023-03-06 | Polymorph forms of aticaprant for use in treating major depressive disorder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025508051A true JP2025508051A (ja) | 2025-03-21 |
| JP2025508051A5 JP2025508051A5 (cg-RX-API-DMAC7.html) | 2026-03-05 |
Family
ID=85706849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024553358A Pending JP2025508051A (ja) | 2022-03-07 | 2023-03-06 | 大うつ病性障害の治療に使用するためのアチカプラントの多形形態 |
Country Status (14)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12161622B2 (en) | 2021-05-04 | 2024-12-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| CA3254546A1 (en) | 2022-03-07 | 2023-09-14 | Janssen Pharmaceuticals, Inc. | COMPOSITIONS CONTAINING ATICAPRANT |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5457208A (en) | 1993-06-21 | 1995-10-10 | Regents Of The University Of Minnesota | Kappa opioid receptor antagonists |
| ES2189759T3 (es) | 1999-05-12 | 2003-07-16 | Hoffmann La Roche | Derivados de imidazoiacepina. |
| US20020052365A1 (en) | 2000-10-05 | 2002-05-02 | Mohler Hanns | Selective anxiolytic therapeutic agents |
| JP2004518654A (ja) | 2000-12-21 | 2004-06-24 | ザ マクレーン ホスピタル コーポレーション | 鬱病の治療法 |
| US6974824B2 (en) | 2001-01-08 | 2005-12-13 | Research Triangle Institute | Kappa opioid receptor ligands |
| WO2003082832A2 (en) | 2002-03-28 | 2003-10-09 | Wisys Technology Foundation, Inc. | Anxiolytic agents with reduced sedative and ataxic effects |
| PT2208727E (pt) | 2002-09-19 | 2012-10-11 | Lilly Co Eli | Éteres diarílicos como antagonista do receptor opióide |
| WO2004080968A1 (en) | 2003-03-07 | 2004-09-23 | Eli Lilly And Company | 6-substituted nicotinamide derivatives as opioid receptor antagonists |
| EP1606275B1 (en) | 2003-03-07 | 2008-08-27 | Eli Lilly And Company | Opioid receptor antagonists |
| CN1890208A (zh) | 2003-12-12 | 2007-01-03 | 伊莱利利公司 | 类鸦片受体拮抗剂 |
| BRPI0417714A (pt) | 2003-12-22 | 2007-03-20 | Lilly Co Eli | composto, composição farmacêutica, e, uso de um composto |
| JP2007528898A (ja) | 2004-03-12 | 2007-10-18 | イーライ リリー アンド カンパニー | オピオイド受容体拮抗物質 |
| AU2005222640A1 (en) | 2004-03-12 | 2005-09-29 | The Mclean Hospital Corporation | Salvinorin derivatives and uses thereof |
| US7381750B2 (en) | 2004-03-12 | 2008-06-03 | Eli Lilly And Company | Amino-phenoxymethyl-benzamide opioid receptor antagonists |
| US7378448B2 (en) | 2004-03-15 | 2008-05-27 | Eli Lilly And Company | Diphenylether amide derivatives as opioid receptor antagonists |
| WO2005090303A1 (en) | 2004-03-15 | 2005-09-29 | Eli Lilly And Company | 4- (5- (aminomethyl) -indole-1-ylmethyl) -benzamide derivatives and related compounds as opioid receptor antagonists for the treatment of obesity |
| US8551986B2 (en) | 2005-12-08 | 2013-10-08 | The Mclean Hospital Corporation | Treatment of sequelae of psychiatric disorders |
| PL2001456T3 (pl) | 2006-04-04 | 2010-05-31 | Emodys Gmbh | Zastosowanie kompozycji zawierających antagonistę receptora opioidowego kappa do leczenia zaburzeń dysocjacyjnych |
| JP2010500372A (ja) | 2006-08-09 | 2010-01-07 | スミスクライン ビーチャム コーポレーション | オピオイド受容体に対するアンタゴニストまたはインバースアゴニストとしての新規化合物 |
| US8633175B2 (en) | 2006-08-09 | 2014-01-21 | Glaxosmithkline Llc | Compounds as antagonists or inverse agonists at opioid receptors |
| MX2009002527A (es) | 2006-09-08 | 2009-03-20 | Pfizer Prod Inc | Derivados de eter diarilico y usos de los mismos. |
| US7709522B2 (en) | 2008-01-22 | 2010-05-04 | Eli Lilly And Company | Kappa selective opioid receptor antagonist |
| US20130303497A1 (en) | 2010-08-05 | 2013-11-14 | Conrig Pharma Aps | Deuterated 5-ht1a receptor agonists |
| WO2013086496A2 (en) | 2011-12-09 | 2013-06-13 | Research Triangle Institute | 1-substituted 4-arylpiperazine as kappa opioid receptor antagonists |
| CA2933733A1 (en) | 2013-12-20 | 2015-06-25 | Connie Sanchez Morillo | Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features |
| US10377698B2 (en) | 2015-03-30 | 2019-08-13 | University Of Innsbruck | Diphenethylamine derivatives which are inter alia useful as analgesics and method for their production |
| WO2016191763A2 (en) | 2015-05-28 | 2016-12-01 | Georgetown University | Use of methadone metabolites for treatment of anxiety and depression |
| EP3468540A4 (en) | 2016-06-13 | 2020-03-18 | Board Of Regents Of the University Of Texas System | PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING PAIN |
| EP3490542A4 (en) | 2016-07-26 | 2020-07-08 | Flagship Pioneering Innovations V, Inc. | NEUROMODULATION COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATION OF AN ANTI-CANCER RESPONSE |
| AU2017325870B2 (en) | 2016-09-16 | 2021-07-22 | Research Traingle Institute | Tetrahydroisoquinoline kappa opioid antagonists |
| US10316021B2 (en) | 2016-11-28 | 2019-06-11 | Pfizer Inc. | Heteroarylphenoxy benzamide kappa opioid ligands |
| DK3596069T3 (da) | 2017-03-17 | 2022-08-01 | Scripps Research Inst | Kappa-opioid-receptor-antagonister og produkter og fremgangsmåder relateret dertil |
| SG10201802129QA (en) | 2017-07-05 | 2019-02-27 | Frimline Private Ltd | A pharmaceutical composition for neuropathic pain |
| US20190255036A1 (en) | 2018-02-16 | 2019-08-22 | Alexander Kariman | Compound and method for reducing neuropathic pain and depression |
| US11820835B2 (en) | 2018-03-23 | 2023-11-21 | University Of Kansas | Cyclic tetrapeptide analogs |
| US11491144B2 (en) | 2018-03-30 | 2022-11-08 | The Florida State University Research Foundation, Incorporated | Methods of treating fragile X mental retardation syndrome |
| US11103171B2 (en) | 2018-10-23 | 2021-08-31 | BlackThor Therapeutics, Ine. | Systems and methods for screening, diagnosing, and stratifying patients |
| US20200171025A1 (en) | 2018-11-29 | 2020-06-04 | Srinivasa Rao Parella | Pharmaceutical composition comprising brexpiprazole and process for preparation thereof |
| US11266627B1 (en) * | 2021-05-04 | 2022-03-08 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| CN114195693A (zh) * | 2020-09-17 | 2022-03-18 | 广东东阳光药业有限公司 | 一种酰胺化合物的晶型及其制备方法 |
| WO2022234457A1 (en) * | 2021-05-04 | 2022-11-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| US12161622B2 (en) | 2021-05-04 | 2024-12-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| CA3254546A1 (en) | 2022-03-07 | 2023-09-14 | Janssen Pharmaceuticals, Inc. | COMPOSITIONS CONTAINING ATICAPRANT |
| EP4489748A1 (en) | 2022-03-07 | 2025-01-15 | Janssen Pharmaceuticals, Inc. | Pure forms of crystalline aticaprant |
-
2023
- 2023-03-06 CN CN202380038808.6A patent/CN119156211A/zh active Pending
- 2023-03-06 CA CA3254365A patent/CA3254365A1/en active Pending
- 2023-03-06 WO PCT/IB2023/052088 patent/WO2023170550A1/en not_active Ceased
- 2023-03-06 US US18/178,961 patent/US11998524B2/en active Active
- 2023-03-06 AU AU2023232536A patent/AU2023232536A1/en active Pending
- 2023-03-06 TW TW112108148A patent/TW202345796A/zh unknown
- 2023-03-06 KR KR1020247033176A patent/KR20240156409A/ko active Pending
- 2023-03-06 IL IL315409A patent/IL315409A/en unknown
- 2023-03-06 JP JP2024553358A patent/JP2025508051A/ja active Pending
- 2023-03-06 EP EP23712343.5A patent/EP4489747A1/en active Pending
-
2024
- 2024-05-31 US US18/679,720 patent/US12171743B2/en active Active
- 2024-09-02 CL CL2024002627A patent/CL2024002627A1/es unknown
- 2024-09-05 JO JOJO/P/2024/0197A patent/JOP20240197A1/ar unknown
- 2024-09-06 MX MX2024010980A patent/MX2024010980A/es unknown
- 2024-09-06 CO CONC2024/0012158A patent/CO2024012158A2/es unknown
- 2024-12-23 US US18/991,891 patent/US20250325515A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250325515A1 (en) | 2025-10-23 |
| CO2024012158A2 (es) | 2024-09-30 |
| US20230277499A1 (en) | 2023-09-07 |
| JOP20240197A1 (ar) | 2024-09-05 |
| TW202345796A (zh) | 2023-12-01 |
| US20240316003A1 (en) | 2024-09-26 |
| US12171743B2 (en) | 2024-12-24 |
| AU2023232536A1 (en) | 2024-10-24 |
| CN119156211A (zh) | 2024-12-17 |
| MX2024010980A (es) | 2024-12-06 |
| EP4489747A1 (en) | 2025-01-15 |
| CA3254365A1 (en) | 2023-09-14 |
| WO2023170550A1 (en) | 2023-09-14 |
| IL315409A (en) | 2024-11-01 |
| KR20240156409A (ko) | 2024-10-29 |
| US11998524B2 (en) | 2024-06-04 |
| CL2024002627A1 (es) | 2025-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250325515A1 (en) | Forms Of Aticaprant | |
| CN117771252A (zh) | 神经活性甾类及其使用方法 | |
| CA3079259A1 (en) | Ganaxolone for use in treating genetic epileptic disorders | |
| JP7627963B2 (ja) | テトラヒドロ-n,n-ジメチル-2,2-ジフェニル-3-フランメタンアミン(anavex2-73)のエナンチオマーならびにシグマ1レセプターにより調節されるアルツハイマー型および他の傷害の処置におけるその使用 | |
| JP2025508071A (ja) | 純粋な形態の結晶質アチカプラント | |
| JP2025508069A (ja) | アチカプラントを含む組成物 | |
| AU2016370499B2 (en) | Amorphous onapristone compositions and methods of making the same | |
| DE69607904T2 (de) | Potenzierung von Serotonin-Wirkstoffresponz | |
| US12324796B2 (en) | Sleep-improving compositions and methods of use | |
| KR20150020160A (ko) | 과민성 방광의 치료를 위한 무스카린 수용체 길항제 및 베타―3 아드레날린 수용체 작용제의 조합물 | |
| CN116514797A (zh) | 美托哌丙嗪的新型多晶型形式 | |
| JP2016506918A (ja) | イソメテプテン異性体 | |
| EA053068B1 (ru) | Полиморфные формы атикапранта для применения при лечении большого депрессивного расстройства | |
| JP2017141279A (ja) | 網膜色素変性症(rp)を治療するための薬剤の製造のための化合物の使用 | |
| KR20260065892A (ko) | 주요 우울 장애의 치료에 사용하기 위한 아티카프란트를 포함하는 조성물 | |
| JP2008127365A (ja) | アレルギー性疾患の予防及び/又は治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260225 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20260225 |